Permissive microbiome characterizes human subjects with a neurovascular disease cavernous angioma
Sean P Polster, Anukriti Sharma, Ceylan Tanes, Alan T Tang, Patricia Mericko, Ying Cao, Julián Carrión-Penagos, Romuald Girard, Janne Koskimäki, Dongdong Zhang, Agnieszka Stadnik, Sharbel G Romanos, Seán B Lyne, Robert Shenkar, Kimberly Yan, Cornelia Lee, Amy Akers, Leslie Morrison, Myranda Robinson, Atif Zafar, Kyle Bittinger, Helen Kim, Jack A Gilbert, Mark L Kahn, Le Shen, Issam A Awad, Sean P Polster, Anukriti Sharma, Ceylan Tanes, Alan T Tang, Patricia Mericko, Ying Cao, Julián Carrión-Penagos, Romuald Girard, Janne Koskimäki, Dongdong Zhang, Agnieszka Stadnik, Sharbel G Romanos, Seán B Lyne, Robert Shenkar, Kimberly Yan, Cornelia Lee, Amy Akers, Leslie Morrison, Myranda Robinson, Atif Zafar, Kyle Bittinger, Helen Kim, Jack A Gilbert, Mark L Kahn, Le Shen, Issam A Awad
Abstract
Cavernous angiomas (CA) are common vascular anomalies causing brain hemorrhage. Based on mouse studies, roles of gram-negative bacteria and altered intestinal homeostasis have been implicated in CA pathogenesis, and pilot study had suggested potential microbiome differences between non-CA and CA individuals based on 16S rRNA gene sequencing. We here assess microbiome differences in a larger cohort of human subjects with and without CA, and among subjects with different clinical features, and conduct more definitive microbial analyses using metagenomic shotgun sequencing. Relative abundance of distinct bacterial species in CA patients is shown, consistent with postulated permissive microbiome driving CA lesion genesis via lipopolysaccharide signaling, in humans as in mice. Other microbiome differences are related to CA clinical behavior. Weighted combinations of microbiome signatures and plasma inflammatory biomarkers enhance associations with disease severity and hemorrhage. This is the first demonstration of a sensitive and specific diagnostic microbiome in a human neurovascular disease.
Conflict of interest statement
The authors declare no competing interests.
Figures
References
- Awad IA, Polster SP. Cavernous angiomas: deconstructing a neurosurgical disease. J. Neurosurg. 2019;131:1–13. doi: 10.3171/2019.3.JNS181724.
- Akers A, et al. Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. Neurosurgery. 2017;80:665–680. doi: 10.1093/neuros/nyx091.
- Wei Shu, Li Ye, Polster Sean P., Weber Christopher R., Awad Issam A., Shen Le. Cerebral Cavernous Malformation Proteins in Barrier Maintenance and Regulation. International Journal of Molecular Sciences. 2020;21(2):675. doi: 10.3390/ijms21020675.
- Laberge-le Couteulx S, et al. Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas. Nat. Genet. 1999;23:189–193. doi: 10.1038/13815.
- Sahoo T, et al. Mutations in the gene encoding KRIT1, a Krev-1/rap1a binding protein, cause cerebral cavernous malformations (CCM1) Hum. Mol. Genet. 1999;8:2325–2333. doi: 10.1093/hmg/8.12.2325.
- Liquori CL, et al. Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations. Am. J. Hum. Genet. 2003;73:1459–1464. doi: 10.1086/380314.
- Denier C, et al. Mutations within the MGC4607 gene cause cerebral cavernous malformations. Am. J. Hum. Genet. 2004;74:326–337. doi: 10.1086/381718.
- Bergametti F, et al. Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am. J. Hum. Genet. 2005;76:42–51. doi: 10.1086/426952.
- Guclu B, et al. Mutations in apoptosis-related gene, PDCD10, cause cerebral cavernous malformation 3. Neurosurgery. 2005;57:1008–1013. doi: 10.1227/01.NEU.0000180811.56157.E1.
- McDonald DA, et al. Lesions from patients with sporadic cerebral cavernous malformations harbor somatic mutations in the CCM genes: evidence for a common biochemical pathway for CCM pathogenesis. Hum. Mol. Genet. 2014;23:4357–4370. doi: 10.1093/hmg/ddu153.
- Draheim KM, Fisher OS, Boggon TJ, Calderwood DA. Cerebral cavernous malformation proteins at a glance. J. Cell Sci. 2014;127:701–707. doi: 10.1242/jcs.138388.
- Choquet H, et al. Association of cardiovascular risk factors with disease severity in cerebral cavernous malformation type 1 subjects with the common Hispanic mutation. Cerebrovasc. Dis. 2014;37:57–63. doi: 10.1159/000356839.
- Choquet H, et al. Polymorphisms in inflammatory and immune response genes associated with cerebral cavernous malformation type 1 severity. Cerebrovasc. Dis. 2014;38:433–440. doi: 10.1159/000369200.
- Al-Shahi Salman R, et al. Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study. Lancet Neurol. 2012;11:217–224. doi: 10.1016/S1474-4422(12)70004-2.
- Shi CB, et al. Immune complex formation and in situ B-cell clonal expansion in human cerebral cavernous malformations. J. Neuroimmunol. 2014;272:67–75. doi: 10.1016/j.jneuroim.2014.04.016.
- Shi C, et al. B-cell depletion reduces the maturation of cerebral cavernous malformations in murine models. J. Neuroimmune Pharmacol. 2016;11:369–377. doi: 10.1007/s11481-016-9670-0.
- Girard R, et al. Plasma biomarkers of inflammation reflect seizures and hemorrhagic activity of cerebral cavernous malformations. Transl. Stroke Res. 2018;9:34–43. doi: 10.1007/s12975-017-0561-3.
- Girard R, et al. Plasma biomarkers of inflammation and angiogenesis predict cerebral cavernous malformation symptomatic hemorrhage or lesional growth. Circ. Res. 2018;122:1716–1721. doi: 10.1161/CIRCRESAHA.118.312680.
- Lyne, S. B. et al. Biomarkers of cavernous angioma with symptomatic hemorrhage. JCI Insight4, 10.1172/jci.insight.128577 (2019).
- Tang AT, et al. Endothelial TLR4 and the microbiome drive cerebral cavernous malformations. Nature. 2017;545:305–310. doi: 10.1038/nature22075.
- Wang Yitang, Li Ye, Zou Jinjing, Polster Sean P., Lightle Rhonda, Moore Thomas, Dimaano Matthew, He Tong-Chuan, Weber Christopher R., Awad Issam A., Shen Le. The cerebral cavernous malformation disease causing gene KRIT1 participates in intestinal epithelial barrier maintenance and regulation. The FASEB Journal. 2018;33(2):2132–2143. doi: 10.1096/fj.201800343R.
- Tang Alan T., Sullivan Katie R., Hong Courtney C., Goddard Lauren M., Mahadevan Aparna, Ren Aileen, Pardo Heidy, Peiper Amy, Griffin Erin, Tanes Ceylan, Mattei Lisa M., Yang Jisheng, Li Li, Mericko-Ishizuka Patricia, Shen Le, Hobson Nicholas, Girard Romuald, Lightle Rhonda, Moore Thomas, Shenkar Robert, Polster Sean P., Roedel Claudia J., Li Ning, Zhu Qin, Whitehead Kevin J., Zheng Xiangjian, Akers Amy, Morrison Leslie, Kim Helen, Bittinger Kyle, Lengner Christopher J., Schwaninger Markus, Velcich Anna, Augenlicht Leonard, Abdelilah-Seyfried Salim, Min Wang, Marchuk Douglas A., Awad Issam A., Kahn Mark L. Distinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformation. Science Translational Medicine. 2019;11(520):eaaw3521. doi: 10.1126/scitranslmed.aaw3521.
- McDonald, D. et al. American Gut: an Open Platform for Citizen Science Microbiome Research. mSystems3, 10.1128/mSystems.00031-18 (2018).
- Callahan BJ, McMurdie PJ, Holmes SP. Exact sequence variants should replace operational taxonomic units in marker-gene data analysis. ISME J. 2017;11:2639–2643. doi: 10.1038/ismej.2017.119.
- Thompson PA, Tobias PS, Viriyakosol S, Kirkland TN, Kitchens RL. Lipopolysaccharide (LPS)-binding protein inhibits responses to cell-bound LPS. J. Biol. Chem. 2003;278:28367–28371. doi: 10.1074/jbc.M302921200.
- Lamping N, et al. LPS-binding protein protects mice from septic shock caused by LPS or Gram-negative bacteria. J. Clin. Invest. 1998;101:2065–2071. doi: 10.1172/JCI2338.
- Knapp S, Florquin S, Golenbock DT, van der Poll T. Pulmonary lipopolysaccharide (LPS)-binding protein inhibits the LPS-induced lung inflammation in vivo. J. Immunol. 2006;176:3189–3195. doi: 10.4049/jimmunol.176.5.3189.
- Sokol H, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl Acad. Sci. USA. 2008;105:16731–16736. doi: 10.1073/pnas.0804812105.
- Miquel S, et al. Faecalibacterium prausnitzii and human intestinal health. Curr. Opin. Microbiol. 2013;16:255–261. doi: 10.1016/j.mib.2013.06.003.
- O’Callaghan, A. & van Sinderen, D. Bifidobacteria and their role as members of the human gut microbiota. Front. Microbiol.7, 10.3389/fmicb.2016.00925 (2016).
- Haran, J. P. et al. Alzheimer’s disease microbiome is associated with dysregulation of the anti-inflammatory P-glycoprotein pathway. Mbio10, 10.1128/mBio.00632-19 (2019).
- Yoshida N, et al. Bacteroides vulgatus and Bacteroides dorei reduce gut microbial lipopolysaccharide production and inhibit atherosclerosis. Circulation. 2018;138:2486–2498. doi: 10.1161/CIRCULATIONAHA.118.033714.
- Vatanen T, et al. Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. Cell. 2016;165:1551. doi: 10.1016/j.cell.2016.05.056.
- Jiang W, et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci. Rep. 2015;5:8096. doi: 10.1038/srep08096.
- Wu GD, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334:105–108. doi: 10.1126/science.1208344.
- Wu Gary D, Lewis James D, Hoffmann Christian, Chen Ying-Yu, Knight Rob, Bittinger Kyle, Hwang Jennifer, Chen Jun, Berkowsky Ronald, Nessel Lisa, Li Hongzhe, Bushman Frederic D. Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16S sequence tags. BMC Microbiology. 2010;10(1):206. doi: 10.1186/1471-2180-10-206.
- Kim D, et al. Optimizing methods and dodging pitfalls in microbiome research. Microbiome. 2017;5:52. doi: 10.1186/s40168-017-0267-5.
- Bolyen E, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat. Biotechnol. 2019;37:852–857. doi: 10.1038/s41587-019-0209-9.
- Amir, A. et al. Deblur rapidly resolves single-nucleotide community sequence patterns. mSystems2, 10.1128/mSystems.00191-16 (2017).
- Mandal S, et al. Analysis of composition of microbiomes: a novel method for studying microbial composition. Microb. Ecol. Health Dis. 2015;26:27663.
- Truong DT, et al. MetaPhlAn2 for enhanced metagenomic taxonomic profiling. Nat. Methods. 2015;12:902–903. doi: 10.1038/nmeth.3589.
- Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat. Methods. 2012;9:357–359. doi: 10.1038/nmeth.1923.
- Franzosa EA, et al. Species-level functional profiling of metagenomes and metatranscriptomes. Nat. Methods. 2018;15:962–968. doi: 10.1038/s41592-018-0176-y.
- Kursa MB, Rudnicki WR. Feature selection with the Boruta package. J. Stat. Softw. 2010;36:1–13. doi: 10.18637/jss.v036.i11.
- Ritchie ME, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47. doi: 10.1093/nar/gkv007.
Source: PubMed